Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGNNASDAQ:EMBCNASDAQ:EYENYSE:NVRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$11.39+0.3%$11.61$7.33▼$21.00$518.70M1.04494,481 shs389,381 shsEMBCEmbecta$10.32+2.9%$10.87$9.20▼$21.48$603.13M1.08497,044 shs153,812 shsEYENational Vision$24.35+4.4%$19.91$9.56▼$24.82$1.92B1.271.91 million shs1.65 million shsNVRONevro$5.85+0.1%$5.85$3.17▼$10.37$224.32M0.81800,223 shs753,602 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen+4.03%+4.70%+4.03%-28.60%+50.66%EMBCEmbecta-2.81%+3.51%+2.45%-12.78%-12.48%EYENational Vision-2.36%+1.39%+10.94%+114.43%+90.29%NVRONevro0.00%0.00%0.00%0.00%-32.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen1.9869 of 5 stars3.52.00.00.00.02.50.6EMBCEmbecta4.1121 of 5 stars3.21.03.30.00.03.33.8EYENational Vision2.4023 of 5 stars2.22.00.03.31.50.80.0NVRONevro0.1708 of 5 stars1.00.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$24.50115.10% UpsideEMBCEmbecta 2.33Hold$19.3387.34% UpsideEYENational Vision 2.56Moderate Buy$21.10-13.35% DownsideNVRONevro 1.92Reduce$5.36-8.29% DownsideCurrent Analyst Ratings BreakdownLatest NVRO, EYE, AXGN, and EMBC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025EYENational VisionUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy7/8/2025EYENational VisionNational BanksharesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$30.007/8/2025EYENational VisionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $30.006/18/2025EYENational VisionBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.005/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/19/2025EYENational VisionBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetMarket Perform ➝ Market Perform$13.00 ➝ $19.005/13/2025AXGNAxoGenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $24.005/12/2025EYENational VisionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$14.00 ➝ $17.005/9/2025EYENational VisionThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$13.00 ➝ $17.005/9/2025EYENational VisionCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$13.00 ➝ $21.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$187.34M2.77N/AN/A$2.36 per share4.83EMBCEmbecta$1.08B0.56$3.34 per share3.09($12.80) per share-0.81EYENational Vision$1.82B1.06$1.67 per share14.61$10.37 per share2.35NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$9.96M-$0.15N/AN/AN/A-3.68%-7.09%-3.67%8/6/2025 (Estimated)EMBCEmbecta$78.30M$0.9011.473.360.664.89%-19.67%12.27%8/8/2025 (Estimated)EYENational Vision-$28.50M-$0.33N/A90.193.50-1.40%3.44%1.40%8/6/2025 (Estimated)NVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)Latest NVRO, EYE, AXGN, and EMBC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 million5/7/2025Q1 2025EYENational Vision$0.32$0.34+$0.02$0.18$510.30 million$510.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/AEMBCEmbecta$0.605.81%N/A66.67%N/AEYENational VisionN/AN/AN/AN/AN/ANVRONevroN/AN/AN/AN/AN/ALatest NVRO, EYE, AXGN, and EMBC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.634.282.65EMBCEmbectaN/A2.481.83EYENational Vision0.290.540.35NVRONevro0.675.023.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%EMBCEmbecta93.83%EYENational VisionN/ANVRONevro95.52%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%EMBCEmbecta0.42%EYENational Vision2.70%NVRONevro3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45045.54 million44.28 millionOptionableEMBCEmbecta2,10058.44 million58.20 millionOptionableEYENational Vision13,41179.05 million76.92 millionOptionableNVRONevro1,09038.37 million36.27 millionOptionableNVRO, EYE, AXGN, and EMBC HeadlinesRecent News About These CompaniesNevro Corp. (NYSE:NVRO) Receives Average Rating of "Reduce" from AnalystsJuly 6 at 3:29 AM | americanbankingnews.comCritical Analysis: Nevro (NYSE:NVRO) & H-CYTE (OTCMKTS:HCYTD)June 29, 2025 | americanbankingnews.comZimmer hires former Nevro CEO Kevin ThornalMay 27, 2025 | medtechdive.comMNevro Corp. Data Breach - Levi & Korsinsky, LLP Launches InvestigationApril 22, 2025 | accessnewswire.comANevro Corp. Data Breach under Investigation by Levi & Korsinsky, LLPApril 21, 2025 | accessnewswire.comAINVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data BreachApril 21, 2025 | accessnewswire.comANevro Corp. Data Breach - Levi & Korsinsky, LLP Launches InvestigationApril 18, 2025 | accessnewswire.comANevro Corp. Data Breach - Levi & Korsinsky, LLP Launches InvestigationApril 17, 2025 | accessnewswire.comANevro Corp. Data Breach Under Investigation by Levi & Korsinsky, LLPApril 16, 2025 | accessnewswire.comAINVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data BreachApril 15, 2025 | accessnewswire.comALevi & Korsinsky, LLP Investigates Nevro Corp. Data BreachApril 14, 2025 | accessnewswire.comALevi & Korsinsky, LLP Investigates Nevro Corp. Data BreachApril 14, 2025 | accessnewswire.comAINVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data BreachApril 11, 2025 | accessnewswire.comADATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Nevro Corp. Customers Whose Data May Have Been CompromisedApril 10, 2025 | globenewswire.comINVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data BreachApril 10, 2025 | accessnewswire.comANevro Corp. Data Breach - Levi & Korsinsky, LLP Launches InvestigationApril 9, 2025 | accessnewswire.comAINVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation of Nevro Corp. Data BreachApril 8, 2025 | accessnewswire.comANevro Files Notice of Data Breach Affecting Confidential Consumer InformationApril 5, 2025 | jdsupra.comNevro Corp. Investigated by Federman & Sherwood for Data BreachApril 3, 2025 | globenewswire.comWhy Is Nevro (NVRO) Up 0.9% Since Last Earnings Report?April 3, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionBy Dan Schmidt | July 2, 2025View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionToast Stock: A Fast-Growing Mid-Cap Eyeing Further UpsideBy Ryan Hasson | July 1, 2025View Toast Stock: A Fast-Growing Mid-Cap Eyeing Further UpsideRobinhood Director Sells Millions, But HOOD Stock Eyes GainsBy Gabriel Osorio-Mazilli | June 19, 2025View Robinhood Director Sells Millions, But HOOD Stock Eyes GainsCrowdStrike Eyes Breakout as Cyber Threats Boost DemandBy Chris Markoch | June 24, 2025View CrowdStrike Eyes Breakout as Cyber Threats Boost DemandSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesBy Leo Miller | June 18, 2025View Sarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesNVRO, EYE, AXGN, and EMBC Company DescriptionsAxoGen NASDAQ:AXGN$11.39 +0.03 (+0.26%) As of 01:22 PM EasternAxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Embecta NASDAQ:EMBC$10.32 +0.29 (+2.89%) As of 01:20 PM EasternEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.National Vision NASDAQ:EYE$24.35 +1.02 (+4.37%) As of 01:22 PM EasternNational Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.Nevro NYSE:NVRO$5.85 +0.01 (+0.10%) Closing price 04/2/2025Extended Trading$5.85 0.00 (0.00%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
